Treatment-Related Interstitial Lung Disease

Experts reflect on the importance of multidisciplinary care and outline the many disciplines involved in diagnosing and treating breast cancer.

Comprehensive details on how multidisciplinary care is applied during a patient’s treatment journey, with a focus on pulmonology and critical care.

Shared insight on how nuanced multidisciplinary care can positively impact outcomes when treating a patient with breast cancer.

Focusing on the value of electronic systems and tumor boards, experts detail how best to communicate across disciplines in the management of breast cancer.

Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.

An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.

In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.

Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.

Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.

Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.

Key opinion leaders share risk-benefit considerations when utilizing therapies that may increase a patient’s risk of developing ILD.

Shared insight on the benefit of multidisciplinary care and the pulmonologist’s role in identifying and managing interstitial lung disease.

Experts highlight key messages regarding optimal identification and management of interstitial lung disease.